Gevo shares jump as Q3 results top estimates, posts positive EBITDA
Investing.com - Guggenheim initiated coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and a price target of $8.00 on Thursday. According to InvestingPro data, the stock is currently trading below its Fair Value, with analyst targets ranging from $3 to $50.
The research firm cited the potential of C4’s oral drug cemsidomide for multiple myeloma, suggesting the treatment could have significant market value despite competition from larger pharmaceutical companies like Bristol Myers Squibb.
Guggenheim noted that cemsidomide may offer several advantages over competing therapies, including a wider therapeutic index, better activity in late-line myeloma patients previously treated with T cell therapies, and fewer dosing complications from neutropenia.
The firm highlighted that C4 Therapeutics has already reported preliminary data showing cemsidomide achieved a 40-50% overall response rate, with complete phase 1 data expected to be released on September 20 at the International Myeloma Society meeting.
Guggenheim’s analysis suggests cemsidomide could potentially be combined more easily with other myeloma treatments without compromising dose intensity, addressing a legitimate market opportunity in multiple myeloma treatment that now includes high-single-digit lines of therapy.
In other recent news, C4 Therapeutics, Inc. announced plans to host a webcast to discuss data from its Phase 1 dose escalation trial of cemsidomide in patients with multiple myeloma. The webcast is scheduled for September 20, 2025, at 3 p.m. ET. This presentation will follow the initial presentation of the data at the International Myeloma Society Annual Meeting in Toronto. Dr. Binod Dhakal from the Medical College of Wisconsin is set to deliver an oral presentation on the updated results of the trial. The study investigates the effects of cemsidomide, a novel MonoDAC degrader, in combination with dexamethasone for patients with relapsed or refractory multiple myeloma. These developments are part of C4 Therapeutics’ ongoing efforts to advance its therapeutic pipeline. Investors and stakeholders may find this information relevant as it highlights the company’s progress in clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.